Regulation / Healthcare Regulatory
Life-science companies, whether global corporations or startups, are forced to operate in a highly regulated industry. This often creates complex legal challenges.
Improper application of regulatory requirements may prolong a company’s product’s go-to-market, thereby affecting both return on investment and patient health. It may also have legal implications.
Understanding the importance of regulation, Barnea strives to provide comprehensive legal regulatory services to Israeli and foreign companies operating in the healthcare field. We represent clients working in biotechnology, medical instrumentation, pharmaceuticals, diagnostic instrumentation, imaging, and more.
Our counsel covers both legal and regulatory issues, including intellectual property, privacy, and consumer protection. We also advise clients in the process of adjusting and assimilating changes to regulatory requirements.
We offer companies services that span across R&D, product registration, licensing and grant applications, and distribution and marketing.
Insights & News - Regulation / Healthcare Regulatory:
Barnea: Representing Pronto Diagnostics and Owners in Sale to Novolog
Sagi Gross and Dor Levi-Tam represented Pronto Diagnostics and its owners in a transaction to sell control of the company to Novolog. Pronto operates in the field of molecular genetic diagnostics.
Barnea: Representing Neve Pharma in Sale to Diplomat for NIS 81 Million
Neve Pharma is engaged in the development, marketing, and sale of nutritional supplements, as well as medical accessories in the ENT field. Sixty-five percent of the company was recently sold to the public company Diplomat for NIS 81 million. Neve Pharma was represented by Sagi Gross, Dor Levi-Tam, and Izabel Pashayev in the transaction.
BioGenCell Completes USD 16 Million Seed Round
Our firm represents BioGenCell, a stem cell research and development company located at Laniado Hospital. The company recently announced the completion of a USD 16 million seed round investment, aided by counsel from Advs. Itay Gura, Ido Freund, and Inbar Katzir. Our firm has represented the company since its inception.
Regulation / Healthcare Regulatory
Life-science companies, whether global corporations or startups, are forced to operate in a highly regulated industry. This often creates complex legal challenges.
Improper application of regulatory requirements may prolong a company’s product’s go-to-market, thereby affecting both return on investment and patient health. It may also have legal implications.
Understanding the importance of regulation, Barnea strives to provide comprehensive legal regulatory services to Israeli and foreign companies operating in the healthcare field. We represent clients working in biotechnology, medical instrumentation, pharmaceuticals, diagnostic instrumentation, imaging, and more.
Our counsel covers both legal and regulatory issues, including intellectual property, privacy, and consumer protection. We also advise clients in the process of adjusting and assimilating changes to regulatory requirements.
We offer companies services that span across R&D, product registration, licensing and grant applications, and distribution and marketing.
Insights & News - Regulation:
Barnea: Representing Pronto Diagnostics and Owners in Sale to Novolog
Sagi Gross and Dor Levi-Tam represented Pronto Diagnostics and its owners in a transaction to sell control of the company to Novolog. Pronto operates in the field of molecular genetic diagnostics.
Barnea: Representing Neve Pharma in Sale to Diplomat for NIS 81 Million
Neve Pharma is engaged in the development, marketing, and sale of nutritional supplements, as well as medical accessories in the ENT field. Sixty-five percent of the company was recently sold to the public company Diplomat for NIS 81 million. Neve Pharma was represented by Sagi Gross, Dor Levi-Tam, and Izabel Pashayev in the transaction.
BioGenCell Completes USD 16 Million Seed Round
Our firm represents BioGenCell, a stem cell research and development company located at Laniado Hospital. The company recently announced the completion of a USD 16 million seed round investment, aided by counsel from Advs. Itay Gura, Ido Freund, and Inbar Katzir. Our firm has represented the company since its inception.